SignatureFD’s ANI Pharmaceuticals ANIP Stock Holding History

SignatureFD’s Portfolio ANIP Stock Details ANIP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$3.81K	Hold	46	–	–	﹤0.01%	2951
2026 Q1	$3.54K	Hold	46	–	–	﹤0.01%	2893
2025 Q4	$3.63K	Hold	46	–	–	﹤0.01%	2804
2025 Q3	$4.21K	Hold	46	–	–	﹤0.01%	2738
2025 Q2	$3K	Buy	46 +8	+21%	+$521	﹤0.01%	2752
2025 Q1	$2.54K	Hold	38	–	–	﹤0.01%	2810
2024 Q4	$2.1K	Hold	38	–	–	﹤0.01%	2853
2024 Q3	$2.27K	Hold	38	–	–	﹤0.01%	2807
2024 Q2	$2.42K	Hold	38	–	–	﹤0.01%	2714
2024 Q1	$2.63K	Hold	38	–	–	﹤0.01%	2729
2023 Q4	$2.1K	Hold	38	–	–	﹤0.01%	2748
2023 Q3	$2.21K	Hold	38	–	–	﹤0.01%	2746
2023 Q2	$2.05K	Hold	38	–	–	﹤0.01%	2803
2023 Q1	$1.51K	Sell	38 -23	-38%	-$970	﹤0.01%	2881
2022 Q4	$2.45K	Buy	61 +38	+165%	+$1.43K	﹤0.01%	2738
2022 Q3	$1K	Buy	+23	New	+$787	﹤0.01%	2901

Other funds holding ANIP

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

GACM

Global Alpha Capital Management Montreal, Quebec, Canada $1.67B AUM 35.09% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SignatureFD's ANIP Position: Q2 2026 in Review

SignatureFD held its ANI Pharmaceuticals (ANIP) position steady in Q2 2026 at 46 shares worth $3.81K. The position accounts for ﹤0.01% of the portfolio, ranked #2951.

SignatureFD first reported a position in ANIP in Q3 2022 and has held it in 16 quarters since. The position peaked at $4.21K in Q3 2025. 307 funds tracked by Wall St. Rank hold ANIP as of Q2 2026.

SignatureFD held 46 shares of ANI Pharmaceuticals worth $3.81K as of Q2 2026.
SignatureFD left its ANI Pharmaceuticals share count unchanged in Q2 2026.
ANI Pharmaceuticals made up ﹤0.01% of SignatureFD's portfolio in Q2 2026, its #2951 holding.
SignatureFD first reported a position in ANI Pharmaceuticals in Q3 2022 and has held it in 16 quarters since.
SignatureFD's ANI Pharmaceuticals position peaked at $4.21K in Q3 2025.
307 funds tracked by Wall St. Rank held ANI Pharmaceuticals as of Q2 2026.

Based on SignatureFD's 13F filing for Q2 2026, filed 24 Jul 2026.